Bli medlem
Bli medlem

Du är här

2016-03-15

BioInvent: BioInvent and Oncurious partner with US research consortium to accelerate phase I/IIa trial of TB-403

Lund, Sweden - 15 March 2016 - BioInvent International (BINV) and
Oncurious NV today announce that the companies have signed a
partnership with the Neuroblastoma and Medulloblastoma Translational
Research Consortium (NMTRC). Accessing the NMRTC network of
specialist clinicians will serve to accelerate the enrollment of
patients to the planned phase I/IIa trial of TB-403 in pediatric
patients with rare but life threatening cancers; medulloblastoma,
neuroblastoma, and Ewing's sarcoma. Final preparations to enable
opening the study for enrollment is ongoing.

NMTRC is a collaboration of 25 US academic medical centers, teaching
hospitals and other entities, with the purpose of facilitating and
conducting collaborative research activities and investigations of
new treatments for neuroblastoma, medulloblastoma and other pediatric
cancers. NMTRC is headquartered at Helen DeVos Children's Hospital in
Grand Rapids, MI, USA.

The partnership with NMTRC is a last step in the preparative work by
BioInvent and Oncurious, before initiating their joint Phase I/IIa
clinical program with TB-403.

TB-403 is a humanized monoclonal antibody against placental growth
factor (PlGF). PlGF is expressed in several types of cancer,
including medulloblastoma, neuroblastoma, and Ewings sarcoma. High
expression of the PlGF receptor neuropilin 1 has been shown to
correlate with poor overall survival in medulloblastoma.

A scientific paper in Cell in February 2013 (Cell, 152, 1065-76,
2013), highlighted for the first time that PlGF plays a vital role in
the brain and that its expression is required for the growth and
spread of medulloblastoma. The paper was based on pre-clinical
research conducted by Prof Rakesh Jain from the Massachusetts General
Hospital at Harvard (Boston) and the team of Prof Peter Carmeliet
from VIB/ KU Leuven.

Michael Oredsson, CEO of BioInvent comments: "The collaboration with
NMTRC and its investigator network brings a wealth of experience in
the paediatric oncology field into this project, and takes us one
important step closer to potentially providing a new, targeted
treatment option for a group of patients with a tremendous unmet
medical need."

Patrik De Haes, MD, Executive Chairman of Oncurious nv comments: "This
agreement with NMTRC will give Oncurious and BioInvent access to a
significant number of centers with considerable expertise in treating
children with medulloblastoma. The broad NMTRC clinical network will
be a major positive as we set out to develop TB-403 as a novel
improved treatment for children with medulloblastoma, neuroblastoma
and Ewings sarcoma."

To the editors:

About BioInvent
BioInvent International AB develops immune oncology drugs. With one of
the world's largest antibody libraries, and a unique, proprietary
discovery method, BioInvent can identify the optimal cellular targets
and antibodies for the treatment of various tumor types. BioInvent
has also considerable experience in and a facility for process
development and production of antibodies for clinical studies. This
makes it possible to develop proprietary drug projects, but also to
supply leading international pharmaceutical companies with effective
tools for their drug development. BioInvent currently has three
proprietary projects in or close to clinical development and
partnership agreements with seven global pharmaceutical and biotech
companies. More information is available at www.bioinvent.com.

About the NMTRC
The Neuroblastoma and Medulloblastoma Translational Research
Consortium (NMTRC) is a group of 25 universities and children's
hospitals headquartered at the Helen Devos Children's Hospital, Grand
Rapids. MI, USA that offer a nationwide network of childhood cancer
clinical trials. These trials are based on the research from a group
of closely collaborating investigators who are linked with laboratory
programs developing novel therapies for high-risk neuroblastoma and
medulloblastoma.

NMTRC's mission is to create a national collaborative effort of
researchers, oncologists and family advocates to bring forward new
therapies for children with relapsed neuroblastoma and
medulloblastoma with the goal of improving the quality of life and
survival of children with neuroblastoma and medulloblastoma. More
information on NMTRC can be found at: http://nmtrc.org/

About Oncurious NV
Oncurious NV is an oncology company focused on the development of
innovative medicines for the treatment of pediatric cancers.
Oncurious is a venture between ThromboGenics and VIB, a leading life
science research institute in Flanders, Belgium.

Oncurious plans to initiate a Phase I/IIa clinical program with TB-403
for the treatment of medulloblastoma, a rare, life-threatening brain
tumor that mainly affects children. BioInvent is a co-development
partner for the planned Phase I/IIa TB-403 clinical trial. More
information on Oncurious NV can be found at www.oncurious.com

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)70716 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)
Co. reg. No: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

The press release contains statements about the future, consisting of
subjective assumptions and forecasts for future scenarios.
Predictions for the future only apply as the date they are made and
are, by their very nature, in the same way as research and
development work in the biotech segment, associated with risk and
uncertainty. With this in mind, the actual outcome may deviate
significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein
pursuant to the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 7.00 a.m. CET, on 15
March, 2016.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=344433...
http://mb.cision.com/Main/583/9934392/488633.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.